Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.
Lore Gruenbaum, PhD
Advertisement
Articles by Lore Gruenbaum, PhD
Lore Gruenbaum, PhD, discusses developments in mantle cell lymphoma management that she has her eye on and critical unmet needs in the field.
Lore Gruenbaum, PhD, discusses the FDA approval of brexu-cel for mantle cell lymphoma and its significance for the treatment paradigm.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5